A bibliographic review on the role of succinate in the development of these diseases has been published in the prestigious journal Current Opinion in Microbiology
The Diabetes and Associated Metabolic Diseases Research Group (DIAMET) from the Pere Virgili Health Research Institute (IISPV), together with the spin-off SUCCIPRO, have published a bibliographic review on the role of succinate in the development of inflammatory bowel diseases.
The review, published in the prestigious journal Current Opinion in Microbiology, highlights the potential of this molecule produced by the intestinal microbiota as a therapeutic target for these types of diseases. The article points out how the accumulation of succinate in the intestine is related to an alteration of the gut flora, inflammation, and metabolic disturbances. This review offers a new perspective on how succinate contributes to the development of inflammatory diseases, such as Crohn’s disease and ulcerative colitis.
With this publication, the DIAMET group, led by Dr. Sonia Fernández-Veledo and Dr. Joan Vendrell, along with SUCCIPRO, a spin-off born from the collaboration between IISPV and Universitat Rovira i Virgili (URV), strengthen their position as leaders in the study of microbial metabolites.
You can find more information about the article here: https://www.sciencedirect.com/science/article/abs/pii/S1369527425000219?via%3Dihub.
The Pere Virgili Health Research Institute (IISPV) is the center that manages health and biomedical research in the province of Tarragona. It brings together the university hospitals Joan XXIII of Tarragona, Sant Joan of Reus, Pere Mata Institute of Reus, and Verge de la Cinta Hospital of Tortosa, as well as Universitat Rovira i Virgili.
Since its creation in 2005, the Institute has worked to ensure that biomedical research is translated into high-quality clinical practice for the benefit of patients and the improvement of the population’s health.
More than 600 professionals, including researchers, technicians, and trainees, are part of IISPV, which encompasses 38 research groups distributed across four strategic areas: the Metabolic Diseases and Nutrition area, comprising 16 research groups; the Infection, Immunity, and Environment area, with a total of 10 groups; the Oncology area, including 6 research groups; and the Neurosciences and Mental Health area, integrating 6 research groups.
SUCCIPRO is a biotechnology spin-off company from URV and IISPV dedicated to the development of new succinate-modulating drugs for the treatment of metabolic and inflammatory diseases. Founded in March 2022 and with over 80% of its budget directly allocated to Research and Development, the company is certified as a startup by ENISA and works on a diversified line of pharmaceutical products in early stages of research. The company is supported by numerous research projects such as NEOTEC (SNEO-20231359) and Torres Quevedo (PTQ2022-012572 and PTQ2023-012978 MCIN/AEI/10.13039/501100011033).
Facebook 
Mail 
WhatsApp 
